



General Assembly

February Session, 2024

Raised Bill No. 241

LCO No. 1536



Referred to Committee on PUBLIC HEALTH

Introduced by:
(PH)

***AN ACT CONCERNING THE OFFICE OF HEALTH STRATEGY'S
RECOMMENDATIONS REGARDING 340B PROGRAM
TRANSPARENCY.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective October 1, 2024*) (a) As used in this section,
2 (1) "federal 340B Drug Pricing Program" or "program" means the plan
3 described in Section 340B of the Public Health Service Act, 42 USC 256b,
4 as amended from time to time, and (2) "340B covered entity" means an
5 entity authorized to participate in the federal 340B Drug Pricing
6 Program under 42 USC 256b(a)(4), as amended from time to time.

7 (b) Not later than April 1, 2025, and annually thereafter, each 340B
8 covered entity shall report to the Health Systems Planning Unit of the
9 Office of Health Strategy, in a form and manner prescribed by the
10 executive director of the Office of Health Strategy, information
11 regarding such entity's participation in the federal 340B Drug Pricing
12 Program. Such report shall include the (1) aggregated acquisition cost
13 for prescription drugs obtained under the program, (2) aggregated
14 payment amount received for prescription drugs obtained for and

15 dispensed to patients under the program, (3) aggregated payments
 16 made to pharmacies under contract to dispense prescription drugs
 17 obtained under the program, (4) number of claims for prescription
 18 drugs described in subdivision (2) of this subsection, and (5) if the 340B
 19 covered entity is a hospital licensed pursuant to chapter 368v of the
 20 general statutes, the national drug code number for the fifty most
 21 frequently dispensed prescription drugs by the hospital under the
 22 program. The information required to be reported pursuant to this
 23 subsection shall (A) be disaggregated by payer mix, including, but not
 24 limited to, Medicare, Medicaid and private insurance, as prescribed by
 25 the executive director, and (B) include prescription drugs dispensed by
 26 outpatient facilities that are child sites listed as reimbursable facilities
 27 on a hospital's Medicare cost report.

28 (c) The executive director of the Office of Health Strategy shall post a
 29 summary of the aggregate information received by the unit pursuant to
 30 the provisions of this section on the Office of Health Strategy's Internet
 31 web site.

This act shall take effect as follows and shall amend the following sections:		
---	--	--

Section 1	October 1, 2024	New section
-----------	-----------------	-------------

Statement of Purpose:

To require entities authorized to participate in the federal 340B Drug Pricing Program to report to the Health Systems Planning Unit of the Office of Health Strategy certain information regarding the program, including (1) aggregated acquisition costs, (2) aggregated payment information, (3) the number of claims for prescription drugs under the program, and (4) if the entity is a hospital, the national drug code number for the fifty most frequently dispensed prescription drugs by the hospital under the program.

[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]